ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
NCT ID: NCT06810141
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04630730
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
NCT07064863
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
NCT06350838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rMBCG
1-19.2e8 colony-forming units (CFU) of rMBCG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥18 years old.
2. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).
3. Ineligible to participate in a clinical trial using rMBCG or geographically unable to access a rMBCG clinical trial site.
4. Voluntary written informed consent and agreement to comply with all protocol specified procedures and follow-up evaluations.
Exclusion Criteria
1. Other illness or condition, including laboratory abnormalities, which in the opinion of the Investigator would exclude the participant from participating in this study. This includes, but is not limited to, serious medical conditions or psychiatric illness likely to interfere with participation in the study.
2. Women who are pregnant or nursing. Female participants of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (eg, hysterectomy or tubal ligation). Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmunityBio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Centers of Alabama
Homewood, Alabama, United States
University Urology
Mobile, Alabama, United States
Urology Associates
Mobile, Alabama, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
USC/ Norris Comprehensive Cancer Center
Los Angeles, California, United States
Urology Center of Southern California
Murrieta, California, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Broward Urology Center
Fort Lauderdale, Florida, United States
Genesis Care
Fort Myers, Florida, United States
Cohen Urology
Lake Worth, Florida, United States
Sebring Urology Center
Sebring, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
Albany Urology Clinic and Surgery Center
Albany, Georgia, United States
Emory University
Atlanta, Georgia, United States
Georgia Urology
Atlanta, Georgia, United States
Augusta Urology Associates, LLC
Evans, Georgia, United States
Hawaii Cancer Care
Honolulu, Hawaii, United States
Island Urology Oahu
Honolulu, Hawaii, United States
North Idaho Urology, PLLC
Coeur d'Alene, Idaho, United States
The Urology Clinic
Meridian, Idaho, United States
Advanced Urology Skokie
Skokie, Illinois, United States
Urology of Indiana
Carmel, Indiana, United States
US Urology Partners - Carmel
Greenwood, Indiana, United States
First Urology, P.S.C
Jeffersonville, Indiana, United States
Kansas City Urology Care, PA
Lenexa, Kansas, United States
Louisiana Healthcare Associates
Covington, Louisiana, United States
NRMC Urology Associates
Natchitoches, Louisiana, United States
Willis Knighton Urologic Oncology at Pierremont
Shreveport, Louisiana, United States
Pioneer Valley Urology, P.C.
Springfield, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Comprehensive Urology
Waterford, Michigan, United States
Essentia Health - Duluth Clinic
Duluth, Minnesota, United States
Allina Health Cancer Institute- Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Minnesota Urology
Woodbury, Minnesota, United States
Cancer Partners of Nebraska
Lincoln, Nebraska, United States
The Urology Center, P. C. D/B/A/ UroHealth Partners
Omaha, Nebraska, United States
University Urology of NJ
Hamilton, New Jersey, United States
Advance Urology Associates Enterprises/ HLP Urology Associates
Manasquan, New Jersey, United States
Garden State Urology
Morristown, New Jersey, United States
Capital Health Urology
Pennington, New Jersey, United States
Advanced Urology, Center for Robotic Surgery
Leland, North Carolina, United States
Cleveland Clinic
Garfield Heights, Ohio, United States
Department of Urology, Jefferson Einstein Hospital
Philadelphia, Pennsylvania, United States
Center for Urologic Care of Berks County
Wyomissing, Pennsylvania, United States
Urology Associates of Charleston
Mt. Pleasant, South Carolina, United States
AUC Urologists, LLC
Myrtle Beach, South Carolina, United States
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, United States
The University of Tennessee Medical Center
Knoxville, Tennessee, United States
Rio Grande Urology
El Paso, Texas, United States
The Urology Place
San Antonio, Texas, United States
Danville Urologic Clinic
Danville, Virginia, United States
Potomac Urology
Fairfax, Virginia, United States
Valley Health Urology
Winchester, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Osvaldo Padron, MD
Role: primary
Role: primary
Role: primary
Diane Hader
Role: primary
Role: primary
Linda Brantley
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ResQ132EX-NMIBC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.